KR20250150155A - 빈혈 치료용 조성물 및 방법 - Google Patents

빈혈 치료용 조성물 및 방법

Info

Publication number
KR20250150155A
KR20250150155A KR1020257032098A KR20257032098A KR20250150155A KR 20250150155 A KR20250150155 A KR 20250150155A KR 1020257032098 A KR1020257032098 A KR 1020257032098A KR 20257032098 A KR20257032098 A KR 20257032098A KR 20250150155 A KR20250150155 A KR 20250150155A
Authority
KR
South Korea
Prior art keywords
compound
formula
weight
certain embodiments
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257032098A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 스미스
구루다트 아제이 찬도르카
엔느 이크퐁 에떼
브래들리 존 마로니
샬롯 수잔 하트만
라민 파자네-파
줄라 컨 인리그
Original Assignee
아케비아 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250150155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아케비아 테라퓨틱스 인코포레이티드 filed Critical 아케비아 테라퓨틱스 인코포레이티드
Publication of KR20250150155A publication Critical patent/KR20250150155A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020257032098A 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법 Pending KR20250150155A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562141420P 2015-04-01 2015-04-01
US62/141,420 2015-04-01
US201562270168P 2015-12-21 2015-12-21
US62/270,168 2015-12-21
KR1020247008210A KR102866021B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법
PCT/US2016/025235 WO2016161094A1 (en) 2015-04-01 2016-03-31 Compositions and methods for treating anemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247008210A Division KR102866021B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20250150155A true KR20250150155A (ko) 2025-10-17

Family

ID=57006457

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257032098A Pending KR20250150155A (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법
KR1020177031649A Active KR102647879B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법
KR1020247008210A Active KR102866021B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177031649A Active KR102647879B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법
KR1020247008210A Active KR102866021B1 (ko) 2015-04-01 2016-03-31 빈혈 치료용 조성물 및 방법

Country Status (35)

Country Link
US (3) US11324734B2 (enExample)
EP (2) EP3995138A1 (enExample)
JP (4) JP6929785B2 (enExample)
KR (3) KR20250150155A (enExample)
CN (2) CN107645953B (enExample)
AU (3) AU2016243700B2 (enExample)
BR (1) BR112017021097B1 (enExample)
CL (2) CL2017002456A1 (enExample)
CO (1) CO2017011200A2 (enExample)
CR (2) CR20170450A (enExample)
CU (1) CU20170126A7 (enExample)
CY (1) CY1124869T1 (enExample)
DK (1) DK3277270T3 (enExample)
EA (1) EA036920B1 (enExample)
EC (1) ECSP17073209A (enExample)
ES (1) ES2900481T3 (enExample)
HR (1) HRP20211862T1 (enExample)
HU (1) HUE056958T2 (enExample)
IL (3) IL305910B2 (enExample)
LT (1) LT3277270T (enExample)
MA (1) MA41863A (enExample)
MX (3) MX386796B (enExample)
MY (1) MY192705A (enExample)
NZ (1) NZ735973A (enExample)
PE (1) PE20180189A1 (enExample)
PH (1) PH12017501789B1 (enExample)
PL (1) PL3277270T3 (enExample)
PT (1) PT3277270T (enExample)
SA (1) SA517390054B1 (enExample)
SG (1) SG11201707994UA (enExample)
SI (1) SI3277270T1 (enExample)
TW (4) TWI881714B (enExample)
UA (1) UA123308C2 (enExample)
WO (1) WO2016161094A1 (enExample)
ZA (2) ZA201706681B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044005B8 (en) 2006-06-26 2012-12-05 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (enExample) 2011-06-06 2018-03-17
HRP20240319T1 (hr) 2013-06-13 2024-05-24 Akebia Therapeutics, Inc. Pripravci i postupci za liječenje anemije
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
SI3277270T1 (sl) * 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR20220133176A (ko) 2019-10-31 2022-10-04 아케비아 테라퓨틱스 인코포레이티드 바다두스타트를 사용하는 치료 방법
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021222424A1 (en) * 2020-04-29 2021-11-04 BioAge Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
JP2023532223A (ja) * 2020-06-19 2023-07-27 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットを含んでなる処方物
WO2021257800A1 (en) 2020-06-19 2021-12-23 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
JP2024503377A (ja) * 2021-01-08 2024-01-25 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用した治療方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
KR20230152078A (ko) 2021-03-01 2023-11-02 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
WO2025087208A1 (zh) * 2023-10-24 2025-05-01 杭州安道药业有限公司 缺氧诱导因子-脯酰胺羟基化酶抑制剂(hif-phi)在罕见贫血中的应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (enExample) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
KR20000065090A (ko) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
KR20010042125A (ko) 1998-03-23 2001-05-25 오흘러 로스 제이. 피페리디디닐 및 ｎ-아미디노피페리디닐 유도체
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
IL151788A0 (en) 2000-03-22 2003-04-10 Upjohn Co Oxazolidinone tablet formulation
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
EP1379630B1 (en) 2001-03-21 2012-09-26 Isis Innovation Limited Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
CN1668296A (zh) 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US7163951B2 (en) 2002-08-29 2007-01-16 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
EP1567528A1 (en) 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
TW200609218A (en) 2004-05-31 2006-03-16 Tanabe Seiyaku Co Bicyclic compounds
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
CN101400690A (zh) 2006-01-09 2009-04-01 英国技术集团国际有限公司 低氧诱导因子-1调节剂和相关用途
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
ES2288117B1 (es) 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
EP2044005B8 (en) 2006-06-26 2012-12-05 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2685942A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
US8796253B2 (en) 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009020119A1 (ja) 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. ＨＩＦ－１αおよびＨＩＦ－２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US20110028507A1 (en) 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101932324A (zh) 2007-11-30 2010-12-29 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
MX2011000656A (es) 2008-07-23 2011-02-23 Hoffmann La Roche Compuestos heterociclicos antiviricos.
CN102149703B (zh) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
CN102365281B (zh) 2009-03-31 2014-11-12 橘生药品工业株式会社 中氮茚衍生物及其医药用途
ES2424122T3 (es) 2009-11-06 2013-09-27 Aerpio Therapeutics Inc. Inhibidores de la prolilhidroxilasa
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
ES2606631T3 (es) 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
WO2014075692A1 (en) 2012-11-19 2014-05-22 Azanta A/S Dispersible tablet
AU2014251038A1 (en) * 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
IL296484B2 (en) * 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
HRP20240319T1 (hr) * 2013-06-13 2024-05-24 Akebia Therapeutics, Inc. Pripravci i postupci za liječenje anemije
AU2014306496A1 (en) 2013-08-16 2016-03-03 Ohio State Innovation Foundation Compositions and methods for modulating DNA methylation
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US20160339005A1 (en) 2014-01-23 2016-11-24 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
US10617716B2 (en) 2014-12-16 2020-04-14 Urgo Us, Inc. Hypochlorous acid formulations and methods for treating skin conditions
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
SI3277270T1 (sl) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije

Also Published As

Publication number Publication date
PH12017501789A1 (en) 2018-04-11
EP3277270A1 (en) 2018-02-07
TWI794725B (zh) 2023-03-01
MX2021012155A (es) 2022-08-02
AU2020273282A1 (en) 2020-12-17
HK1248590A1 (zh) 2018-10-19
ZA202006107B (en) 2024-02-28
SG11201707994UA (en) 2017-10-30
KR102866021B1 (ko) 2025-09-30
US11844756B2 (en) 2023-12-19
NZ735973A (en) 2023-06-30
PT3277270T (pt) 2021-12-07
TW202320770A (zh) 2023-06-01
BR112017021097A2 (pt) 2018-07-03
BR112017021097B1 (pt) 2024-01-02
KR102647879B1 (ko) 2024-03-15
PE20180189A1 (es) 2018-01-23
US20180092892A1 (en) 2018-04-05
AU2016243700A1 (en) 2017-10-26
HUE056958T2 (hu) 2022-04-28
CA2981176A1 (en) 2017-10-06
EP3277270A4 (en) 2018-10-31
JP6929785B2 (ja) 2021-09-01
JP2021181478A (ja) 2021-11-25
JP2018510178A (ja) 2018-04-12
JP2025069280A (ja) 2025-04-30
CR20170450A (es) 2018-04-03
EP3995138A1 (en) 2022-05-11
CY1124869T1 (el) 2022-11-25
MX374909B (es) 2025-03-06
US20240325361A1 (en) 2024-10-03
JP7629049B2 (ja) 2025-02-12
MX2017012460A (es) 2018-01-30
CL2019001927A1 (es) 2019-11-29
EA036920B1 (ru) 2021-01-15
CN107645953A (zh) 2018-01-30
TWI881714B (zh) 2025-04-21
CR20210248A (es) 2021-06-01
UA123308C2 (uk) 2021-03-17
IL292262B1 (en) 2023-10-01
PL3277270T3 (pl) 2022-02-14
MX2020009415A (es) 2021-10-04
WO2016161094A1 (en) 2016-10-06
CL2017002456A1 (es) 2018-04-20
KR20170132865A (ko) 2017-12-04
CU20170126A7 (es) 2018-07-05
MA41863A (fr) 2021-06-02
JP2023093684A (ja) 2023-07-04
US11324734B2 (en) 2022-05-10
TW201642839A (zh) 2016-12-16
EP3277270B1 (en) 2021-10-27
SA517390054B1 (ar) 2022-02-22
AU2023200252B2 (en) 2025-03-20
TWI718138B (zh) 2021-02-11
IL254710B (en) 2022-05-01
IL292262A (en) 2022-06-01
IL254710A0 (en) 2017-11-30
CN107645953B (zh) 2022-11-01
CN115607521A (zh) 2023-01-17
AU2023200252A1 (en) 2023-02-16
IL305910B1 (en) 2024-12-01
NZ773901A (en) 2024-07-26
ZA201706681B (en) 2021-02-24
TWI836883B (zh) 2024-03-21
SI3277270T1 (sl) 2022-04-29
PH12017501789B1 (en) 2024-02-16
JP7270688B2 (ja) 2023-05-10
HRP20211862T1 (hr) 2022-03-04
ES2900481T3 (es) 2022-03-17
AU2016243700B2 (en) 2020-08-20
TW202140001A (zh) 2021-11-01
IL292262B2 (en) 2024-02-01
LT3277270T (lt) 2022-01-10
DK3277270T3 (da) 2021-12-06
KR20240038132A (ko) 2024-03-22
CO2017011200A2 (es) 2018-04-19
TW202421140A (zh) 2024-06-01
US20230071553A1 (en) 2023-03-09
MX386796B (es) 2025-03-19
IL305910A (en) 2023-11-01
IL305910B2 (en) 2025-04-01
MY192705A (en) 2022-09-02
EA201792182A1 (ru) 2018-06-29
ECSP17073209A (es) 2017-12-01
AU2020273282B2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US11844756B2 (en) Compositions and methods for treating anemia
AU2014278543B2 (en) Compositions and methods for treating anemia
HK40074484A (en) Compositions and methods for treating anemia
CA2981176C (en) Compositions and methods for treating anemia
HK1248590B (en) Compositions and methods for treating anemia

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000